Profile data is unavailable for this security.
About the company
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj’s business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group’s strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
- Revenue in EUR (TTM)2.96m
- Net income in EUR-21.77m
- Incorporated2015
- Employees173.00
- LocationNanoform Finland OyjCultivator II, Viikinkaari 4HELSINKI 00790FinlandFIN
- Phone+358 293700150
- Fax+358 88706970
- Websitehttps://nanoform.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zelluna ASA | 0.00 | -12.48m | 36.27m | 26.00 | -- | 4.76 | -- | -- | -7.10 | -7.10 | 0.00 | 3.27 | 0.00 | -- | -- | -- | -128.29 | -44.36 | -165.31 | -49.63 | -- | -- | -- | -- | -- | -- | 0.008 | -- | -- | -- | 30.02 | -- | -41.59 | -- |
| Ascelia Pharma AB | 0.00 | -7.20m | 36.48m | 11.00 | -- | 3.92 | -- | -- | -0.693 | -0.693 | 0.00 | 0.7777 | 0.00 | -- | -- | -- | -60.31 | -54.24 | -85.44 | -64.44 | -- | -- | -- | -- | -- | -31.70 | 0.0097 | -- | -- | -- | 4.72 | -- | -32.17 | -- |
| Herantis Pharma Oyj | 0.00 | -5.45m | 47.71m | 13.00 | -- | 27.28 | -- | -- | -0.2417 | -0.2417 | 0.00 | 0.0726 | 0.00 | -- | -- | 0.00 | -124.50 | -81.63 | -166.61 | -107.95 | -- | -- | -- | -- | -- | -17.91 | 0.6101 | -- | -- | -- | -1,865.03 | -- | -- | -- |
| Medivir AB | 376.21k | -7.35m | 49.91m | 10.00 | -- | 2.02 | -- | 132.66 | -0.6789 | -0.6789 | 0.0348 | 0.5831 | 0.0238 | -- | 0.9374 | 398,400.00 | -46.44 | -31.75 | -69.67 | -38.14 | -- | -- | -1,953.24 | -740.12 | -- | -70.04 | 0.00 | -- | -54.36 | -16.77 | -38.06 | -- | -- | -- |
| Lytix Biopharma AS | 33.44k | -6.49m | 64.28m | 6.00 | -- | 8.04 | -- | 1,922.06 | -1.08 | -1.08 | 0.0055 | 1.15 | 0.005 | -- | 0.0579 | 62,833.33 | -96.51 | -61.17 | -123.25 | -71.49 | -- | -- | -19,422.02 | -722.29 | -- | -- | 0.0301 | -- | 178.98 | 104.67 | -7.24 | -- | -- | -- |
| Nanoform Finland Oyj | 2.96m | -21.77m | 66.82m | 173.00 | -- | 1.50 | -- | 22.61 | -0.2613 | -0.2613 | 0.0354 | 0.5203 | 0.0442 | 80.07 | 9.22 | 16,328.73 | -32.55 | -26.72 | -36.27 | -29.06 | -441.87 | -539.46 | -736.69 | -918.61 | 4.30 | -- | 0.1281 | -- | 8.22 | 124.15 | -12.87 | -- | -1.62 | -- |
| Hamlet BioPharma AB | 0.00 | -5.34m | 68.93m | 6.00 | -- | 18.11 | -- | -- | -0.3157 | -0.3157 | 0.00 | 0.2927 | 0.00 | -- | -- | 0.00 | -95.68 | -78.53 | -104.48 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Oncopeptides AB | 5.91m | -25.29m | 72.76m | 75.00 | -- | 117.69 | -- | 12.31 | -1.20 | -1.20 | 0.2798 | 0.0253 | 0.2359 | 0.2049 | 1.79 | 782,225.00 | -100.98 | -148.24 | -125.09 | -215.27 | 97.88 | -- | -428.01 | -2,013.60 | 3.27 | -12.10 | 0.9507 | -- | -10.14 | -- | -14.25 | -- | -7.14 | -- |
| Curasight A/S | -5.98m | -6.46m | 92.72m | 4.00 | -- | 39.64 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
Data as of Feb 16 2026. Currency figures normalised to Nanoform Finland Oyj's reporting currency: Euro EUR
29.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 30 Sep 2025 | 4.27m | 4.98% |
| Fj�rde AP-fondenas of 05 Mar 2025 | 4.05m | 4.72% |
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 26 Feb 2025 | 3.84m | 4.49% |
| Keel Capital ABas of 31 Dec 2024 | 3.70m | 4.31% |
| Arbejdsmarkedets Till�gspension (Investment Management)as of 31 Dec 2024 | 2.70m | 3.15% |
| Sp-Fund Management Co. Ltd.as of 30 Jan 2026 | 2.17m | 2.54% |
| Norges Bank Investment Managementas of 26 Feb 2025 | 1.34m | 1.57% |
| OP Asset Management Ltd.as of 26 Feb 2025 | 1.09m | 1.28% |
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 26 Feb 2025 | 920.46k | 1.07% |
| Mandatum Asset Management Ltd.as of 30 Jun 2025 | 838.55k | 0.98% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
